Advancing Gene Therapy Research for Hemophilia A at MCW
Kristi Castello, Division Administrator III at the Medical College of Wisconsin, reposted from Medical College of Wisconsin on LinkedIn:
Quoting Medical College of Wisconsin‘s post:
”For people with hemophilia A, a simple cut or bump can cause excessive bleeding or bruising. While treatments exist to replace this protein, patients may form antibodies to the current therapies.
For more than two decades, MCW’s David A. Wilcox, PhD has worked with colleagues to develop a new gene therapy that could transform how patients with the disease are treated.
The team has completed preliminary studies of a Phase 1 clinical trial at MCW, ran by MCW’s Dr. Mary Eapen, with a gene therapy that genetically-modifies a patient’s own bone marrow cells to make a blood clotting factor.
Learn more:”
Stay updated with Hemostasis Today.
-
Jun 27, 2026, 13:27Limited-Time Open Access for the EAHAD 2026 Joint Session with ISTH – EAHAD
-
Jun 27, 2026, 13:16Stefano Rivella: Stress Erythropoiesis and the Role of HRG1-Mediated Heme Import
-
Jun 27, 2026, 13:10Yahya Samadi: Luspatercept Shows Promise in Reducing Transfusion Burden in β-Thalassemia
-
Jun 27, 2026, 13:03Margarida Marreiros: Supporting Excellence in Hemostasis Testing
-
Jun 27, 2026, 12:44Maia Meier: Turning Achievement into Advocacy for Women with Bleeding Disorders
-
Jun 27, 2026, 12:38BSH Guideline for the Estimation of Fetomaternal Haemorrhage
-
Jun 27, 2026, 12:34Vishnu K: The Growing Role of RET-He in Modern Hematology
-
Jun 27, 2026, 12:33María Gabriela Muñoz: TOAST Criteria and Outcomes in Ischemic Stroke
-
Jun 27, 2026, 12:17Navid Radfar: Moving Beyond CHA₂DS₂-VASc and De-Risking Atrial Fibrillation